Xenon Pharmaceuticals (XENE) Expected to Release Quarterly Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Xenon Pharmaceuticals to announce earnings of ($1.14) per share and revenue of $1.6670 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the company posted ($0.83) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Xenon Pharmaceuticals Trading Down 2.4%

Xenon Pharmaceuticals stock opened at $62.67 on Friday. The stock has a fifty day moving average price of $59.30 and a 200 day moving average price of $53.40. Xenon Pharmaceuticals has a 52 week low of $30.00 and a 52 week high of $72.66. The firm has a market capitalization of $6.06 billion, a P/E ratio of -13.33 and a beta of 0.61.

Analysts Set New Price Targets

Several analysts have commented on the company. Royal Bank Of Canada lifted their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th. JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $77.20.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.91% of the stock is currently owned by insiders.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Cinctive Capital Management LP lifted its position in Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 263 shares in the last quarter. State of Wyoming grew its stake in Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 350 shares during the period. Quarry LP increased its position in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $33,000. Finally, Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.